<code id='455BF2346C'></code><style id='455BF2346C'></style>
    • <acronym id='455BF2346C'></acronym>
      <center id='455BF2346C'><center id='455BF2346C'><tfoot id='455BF2346C'></tfoot></center><abbr id='455BF2346C'><dir id='455BF2346C'><tfoot id='455BF2346C'></tfoot><noframes id='455BF2346C'>

    • <optgroup id='455BF2346C'><strike id='455BF2346C'><sup id='455BF2346C'></sup></strike><code id='455BF2346C'></code></optgroup>
        1. <b id='455BF2346C'><label id='455BF2346C'><select id='455BF2346C'><dt id='455BF2346C'><span id='455BF2346C'></span></dt></select></label></b><u id='455BF2346C'></u>
          <i id='455BF2346C'><strike id='455BF2346C'><tt id='455BF2346C'><pre id='455BF2346C'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:explore    Page View:9514
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In